17/06/2026 UCB completed acquisition of Candid Therapeutics strengthening next generation immunology pipeline Biogen expanded immunology pipeline with agreement to acquire RayThera UCB completed acquisition of Candid Therapeutics strengthening next generation immunology pipeline (Ref) UCB announced the successful completion of its previously announced acquisition of Candid Therapeutics, a clinical-stage biotechnology company developing novel T-cell engager therapies for autoi

16/06/2026 Avalo Therapeutics added AVTX-010, a long-acting next-generation anti-IL-1β antibody, to Its development pipeline Avalo Therapeutics added AVTX-010, a long-acting next-generation anti-IL-1β antibody, to Its development pipeline (Ref) Avalo Therapeutics announced the advancement of AVTX-010 (anti-IL-1β mAb) with the potential for development in hidradenitis suppurativa (HS) as well as additional inflammatory disorders. The Company expected to submit an Investigation

06/04/2026 Tenvie Therapeutics announced dosing of first subject in Phase 1 trial of TNV262 Amgen announced topline results from Phase 3 teprotumumab in active TED Tenvie Therapeutics announced dosing of first subject in Phase 1 trial of TNV262 ( Ref ) Tenvie Therapeutics announced the first subject dosed in a Phase 1 clinical study evaluating TNV262 (a fully CNS-penetrant small molecule inhibitor targeting NLRP3) for the treatment of cardiometabolic diseases, including obesi

23/03/2026 Gilead Sciences to acquire Ouro Medicines to advance first in class T cell engager program for autoimmune diseases Apogee Therapeutics announced Phase 2 results of zumilokibart in Moderate-to-Severe AD Galapagos and Gilead in advanced discussions to collaborate on advancing first in class T cell engager program for autoimmune diseases Kali Therapeutics announced a worldwide exclusive license agreement with Sanofi for KT501 for autoimmune diseases Gilead Sciences to

22/02/2026 MoonLake announced topline results from its Phase 2 study of sonelokimab in axial spondyloarthritis MoonLake announced topline results from its Phase 2 study of sonelokimab in axial spondyloarthritis ( Ref ) MoonLake Immunotherapeutics announced positive topline results from its Phase 2, S-OLARIS study evaluating sonelokimab (IL-17A and IL-17F inhibitor) in patients with radiographic and non-radiographic axial spondyloarthritis The study demonstrated a clinically m